38 results on '"Raimbaud, Isabelle"'
Search Results
2. Supplementary Figure 1 from Human TH17 Immune Cells Specific for the Tumor Antigen MAGE-A3 Convert to IFN-γ–Secreting Cells as They Differentiate into Effector T Cells In Vivo
3. Supplementary Table 1 from Human TH17 Immune Cells Specific for the Tumor Antigen MAGE-A3 Convert to IFN-γ–Secreting Cells as They Differentiate into Effector T Cells In Vivo
4. Data from CXCR3+ T Regulatory Cells Selectively Accumulate in Human Ovarian Carcinomas to Limit Type I Immunity
5. Supplementary Figure Legend from Human TH17 Immune Cells Specific for the Tumor Antigen MAGE-A3 Convert to IFN-γ–Secreting Cells as They Differentiate into Effector T Cells In Vivo
6. Supplementary Table 2 from Human TH17 Immune Cells Specific for the Tumor Antigen MAGE-A3 Convert to IFN-γ–Secreting Cells as They Differentiate into Effector T Cells In Vivo
7. Supplementary Figure 3 from CXCR3+ T Regulatory Cells Selectively Accumulate in Human Ovarian Carcinomas to Limit Type I Immunity
8. Supplementary Figure 5 from CXCR3+ T Regulatory Cells Selectively Accumulate in Human Ovarian Carcinomas to Limit Type I Immunity
9. Supplementary Figure 6 from CXCR3+ T Regulatory Cells Selectively Accumulate in Human Ovarian Carcinomas to Limit Type I Immunity
10. Supplementary Figure Legends 1-6 from CXCR3+ T Regulatory Cells Selectively Accumulate in Human Ovarian Carcinomas to Limit Type I Immunity
11. Supplementary Figure 2 from CXCR3+ T Regulatory Cells Selectively Accumulate in Human Ovarian Carcinomas to Limit Type I Immunity
12. Supplementary Figure 1 from CXCR3+ T Regulatory Cells Selectively Accumulate in Human Ovarian Carcinomas to Limit Type I Immunity
13. Supplementary Figure 4 from CXCR3+ T Regulatory Cells Selectively Accumulate in Human Ovarian Carcinomas to Limit Type I Immunity
14. Human RORγt⁺ T H 17 cells preferentially differentiate from naive FOXP3⁺Treg in the presence of lineage-specific polarizing factors
15. Monitoring of NY-ESO-1 specific CD4⁺ T cells using molecularly defined MHC class II/His-tag-peptide tetramers
16. Human Memory FOXP3⁺ Tregs Secrete IL-17 ex vivo and Constitutively Express the $T_H $ 17 Lineage-Specific Transcription Factor RORγt
17. Human [ROR[gamma]t.sup.+] [T.sub.H]17 cells preferentially differentiate from naive [FOXP3.sup.+]Treg in the presence of lineage-specific polarizing factors
18. Human memory [FOXP3.sup.+] Tregs secrete IL-17 ex vivo and constitutively express the [T.sub.H]17 lineage-specific transcription factor ROR[gamma]t
19. CXCR3+ T Regulatory Cells Selectively Accumulate in Human Ovarian Carcinomas to Limit Type I Immunity
20. Human TH17 Immune Cells Specific for the Tumor Antigen MAGE-A3 Convert to IFN-γ–Secreting Cells as They Differentiate into Effector T Cells In Vivo
21. Ex Vivo IL-1 Receptor Type I Expression in Human CD4+ T Cells Identifies an Early Intermediate in the Differentiation of Th17 from FOXP3+ Naive Regulatory T Cells
22. NY-ESO-1-Specific Circulating CD4+ T Cells in Ovarian Cancer Patients Are Prevalently TH1 Type Cells Undetectable in the CD25+FOXP3+Treg Compartment
23. Antibody Responses to NY-ESO-1 in Primary Breast Cancer Identify a Subtype Target for Immunotherapy
24. Human RORγt + T H 17 cells preferentially differentiate from naive FOXP3 + Treg in the presence of lineage-specific polarizing factors
25. Assessment of Vaccine-Induced CD4 T Cell Responses to the 119-143 Immunodominant Region of the Tumor-Specific Antigen NY-ESO-1 Using DRB1*0101 Tetramers
26. Monitoring of NY-ESO-1 specific CD4 + T cells using molecularly defined MHC class II/His-tag-peptide tetramers
27. Human memory FOXP3 + Tregs secrete IL-17 ex vivo and constitutively express the T H 17 lineage-specific transcription factor RORγt
28. Human memory FOXP3+ Treg secrete IL-17 ex-vivo and constitutively express the TH17 lineage specific transcription factor RORγt (33.14)
29. Improving rAAV production and purification: towards the definition of a scaleable process
30. A Versatile and Scalable Two-Step Ion-Exchange Chromatography Process for the Purification of Recombinant Adeno-associated Virus Serotypes-2 and -5
31. Ex Vivo IL-i Receptor Type I Expression in Human CD4+ T Cells Identifies an Early Intermediate in the Differentiatioi of Th17 from FOXP3+ Naive Regulatory T Cells.
32. NY-ESO-1-Specific Circulating CD4+ T Cells in Ovarian Cancer Patients Are Prevalently TH1 Type Cells Undetectable in the CD25+ FOXP3+ Treg Compartment.
33. Human RORγt+ TH17 cells preferentially differentiate from naive FOXP3+Treg in the presence of lineage-specific polarizing factors.
34. Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.
35. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the TH17 lineage-specific transcription factor RORγt.
36. CXCR3+ T Regulatory Cells Selectively Accumulate in Human Ovarian Carcinomas to Limit Type I Immunity.
37. Human TH17 Immune Cells Specific for the Tumor Antigen MAGE-A3 Convert to IFN-γ-Secreting Cells as They Differentiate into Effector T Cells In Vivo.
38. NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.